3D Cardiac ECM Scaffold for Cardiomyocyte Maturation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating cardiomyocytes from induced pluripotent stem cells (iPSCs) result in immature cells that lack the maturity and functionality of native cardiomyocytes, hindering tissue repair and drug screening due to disorganized sarcomere structures, weak contraction, improper calcium handling, and altered drug responses.
Innovation Solution
The use of a three-dimensional (3D) cardiac extracellular matrix (ECM) scaffold, generated from adult heart tissue through SDS-mediated decellularization, to induce and promote cardiomyocyte maturation by seeding immature cardiomyocytes within it, along with endothelial and stromal cells, which enhances expression of maturation markers like Junctin, SERCA2a, CaV1.2, NCX1, and Cx43.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pluripotent stem cell-derived cardiomyocytes are generated through current methods, then cardiomyocytes can be produced for tissue replacement and drug screening, but the cells remain immature with disorganized sarcomere structures, weak force contraction, and improper calcium handling
Solution Approach 1:
The patent transitions from traditional two-dimensional monolayer culture to three-dimensional cardiac extracellular matrix scaffolds. This dimensional change provides mechanical cues and spatial organization that mimic the native cardiac environment, promoting sarcomere organization, improved calcium handling, and mature contractile function without requiring complex multi-step differentiation protocols
Solution Approach 2:
The patent modifies physical parameters of the culture environment including substrate stiffness, three-dimensional architecture, and mechanical stretching conditions. These parameter changes induce cardiomyocyte maturation by mimicking physiological mechanical stresses, leading to improved sarcomere structure, enhanced force contraction, and proper calcium handling mechanisms
2Productivity
If immature cardiomyocytes are used for drug screening, then high throughput screening can be performed, but the cells show altered responses to drugs and do not predict efficacy and side effects accurately
Solution Approach 1:
By changing the physical and mechanical parameters of the culture system to three-dimensional matrices with appropriate stiffness and mechanical stimulation, the patent achieves mature drug response profiles that accurately predict clinical efficacy and side effects while maintaining high-throughput screening capabilities
3Loss of time
If current iPSC differentiation methods are used, then cardiomyocytes can be generated rapidly, but the cells display fetal characteristics with automaticity and do not show loss of automaticity seen in mature cardiomyocytes
Solution Approach 1:
The transition to three-dimensional culture provides immediate mechanical cues and cell-cell interaction opportunities that accelerate maturation. The three-dimensional architecture enables proper connexin organization and gap junction formation, leading to loss of automaticity and emergence of mature electrophysiological characteristics within a reasonable timeframe
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively matures cardiomyocytes, improving their contraction strength, calcium handling, and drug responsiveness, making them suitable for tissue engineering and drug screening applications.
Implementation Method 1
the 3D cardiac ECM is generated from a heart tissue of an adult subject through SDS-mediated decellularization
Data Source
AI summary
Disclosed herein are methods of inducing and/or promoting cardiomyocyte maturation comprising: providing an immature cardiomyocyte; providing a three dimensional (3D) cardiac extracellular matrix (ECM) scaffold; and inducing and/or promoting cardiomyocyte cell maturation by seeding the immature cardiomyocyte in the 3D cardiac ECM scaffold and harvesting once the cardiomyocyte has reached maturity. Also disclosed herein are methods of treating a disease in a mammal comprising transplanting a mature cardiomyocyte into an ischemic heart, wherein the mature cardiomyocyte is generated comprising the steps of: providing an immature cardiomyocyte; providing a 3D cardiac ECM scaffold; and generating mature cardiomyocyte by seeding the immature cardiomyocyte in a 3D cardiac ECM scaffold or co-culturing the immature cardiomyocyte in the presence of endothelial cells or stromal cells; and harvesting once the cardiomyocyte has reached maturity.